MSFP
TEVA icon

Mark Sheptoff Financial Planning’s Teva Pharmaceuticals TEVA Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,500
Closed -$78K – 570
2025
Q4 		$78K Buy
+2,500
New +$61.6K 0.04% 169
2025
Q1 		– Sell
-3,000
Closed -$66.1K – 464
2024
Q4 		$66.1K Sell
3,000
-500
-14% -$9.1K 0.04% 155
2024
Q3 		$63.1K Hold
3,500
– – 0.03% 156
2024
Q2 		$56.9K Buy
+3,500
New +$53.9K 0.03% 171
2015
Q3 		– Sell
-42
Closed -$2K – 442
2015
Q2 		$2K Buy
+42
New +$2.59K ﹤0.01% 331

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mark Sheptoff Financial Planning's TEVA Position: Q1 2026 in Review

Mark Sheptoff Financial Planning sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 2,500 shares — an estimated $78K sold.

Mark Sheptoff Financial Planning first reported a position in TEVA in Q2 2015 and held it in 5 quarters. The position peaked at $78K in Q4 2025. 652 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Mark Sheptoff Financial Planning reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mark Sheptoff Financial Planning sold 2,500 Teva Pharmaceuticals shares in Q1 2026, an estimated $78K.
  • Mark Sheptoff Financial Planning first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 5 quarters.
  • Mark Sheptoff Financial Planning's Teva Pharmaceuticals position peaked at $78K in Q4 2025.
  • 652 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Mark Sheptoff Financial Planning's 13F filing for Q1 2026, filed 11 May 2026.